sEH

Soluble expoxide hydrolase (sEH; EC 3.3.2.10) is a key enzyme in the metabolism of eicosanoid epoxides, including epoxyeicosatrienoic acids (EETs)  and of leukotoxin (LTX). EETs, endothelium-derived hyperpolarizing factors, exhibit potentially beneficial properties, including anti-inflammatory effects and vasodilation. The enzyme is a bifunctional homodimeric complex located in both cytosol and peroxisomes with hydrolase and phosphatase activity[1]. GSK2256294A (Axon 2220) is a potent, selective inhibitor of sEH, and attenuates cigarette smoke-induced inflammation by both inhibiting its initiation and/or maintenance and promoting its resolution. GSK2256294A would be an appropriate agent to evaluate the role of sEH in clinical studies, for example in diseases where cigarette smoke is a risk factor, such as chronic obstructive pulmonary disease (COPD) and cardiovascular disease[2].


[1] H.C. Shen. Soluble epoxide hydrolase inhibitors: a patent review. Expert Opin. Ther. Pat. 2010, 20, 941-956.
[2] P.L. Podolin et al. In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid. Mediat. 2013, 104-105, 25-31.

2 Item(s)

per page
Axon ID Name Description From price
2220 GSK 2256294A Potent, reversible, tight binding inhibitor of recombinant human sEH €125.00
3022 TUPS Soluble epoxide hydrolase inhibitor €135.00

2 Item(s)

per page
Please wait...